Table 3.

Summary of adverse event of special interest with secukinumab during the study

	n (%) (N = 306)
	AE	AR
Any incidence	48 (15.7)	36 (11.8)
Serious infections	5 (1.6)	5 (1.6)
Fungal infections	18 (5.9)	18 (5.9)
Tuberculosis	2 (0.7)	2 (0.7)
Neutropenia	3 (1.0)	2 (0.7)
Hypersensitivity reactions	16 (5.2)	9 (2.9)
Malignant tumors	2 (0.7)	1 (0.3)
Inflammatory bowel disease	1 (0.3)	1 (0.3)
Cardiovascular/cerebrovascular events	7 (2.3)	2 (0.7)

Multiple episodes of an event (preferred term) in the same patient are counted only once. MedDRA version 22.0. AE, adverse event; AR, adverse reaction; N, total number of patients; n, number of patients.